Strategic Acquisition of SC Pharma and Revenue Diversification

12 days ago

Mike Castana

"Yeah, you know, I think you hit the nail on the head. Like we, we want to keep building this company, growing a great company, having a great culture. Um we'll have offices in Connecticut, Boston now, and here in California. Um, one of the things we have to do is diversify our revenue streams, right? You come to a quarterly earnings and two thirds of your revenues are from United Therapeutics. And until our pipeline hits, which will start happening pretty quickly now, we were stuck at their mercy. We were looking for an active revenue stream that we could add value to and was already product approved. SC Pharma popped up, and they were short on cash and capabilities. We believe that combining what we built on Fresza with what they have, where we go with our strategy, is going to turn one plus one into three or four."

The CEO emphasizes the strategic rationale behind acquiring SC Pharma to diversify revenue away from heavy reliance on United Therapeutics. By integrating SC Pharma’s cash-starved but approved product with Mankind’s existing strengths, the company aims to create outsized combined value and reduce regulatory and commercial risks in the near to medium term.

Related Stocks